

# Current Disease-Modifying Therapies in Multiple Sclerosis

Bernd C. Kieseier, M.D.,<sup>1</sup> and Hans-Peter Hartung, M.D.<sup>1</sup>

The publisher regrets an error in Table 2 of the above article in *Seminars in Neurology*, Volume 23, Number 2, p. 142. On the last line of column one, under the heading “Clinical Subform,” the entry *Primary-relapsing MS* should read *Relapsing progressive MS*. The corrected table appears below.

**Table 2 Current Treatment Strategies in Multiple Sclerosis (MS)**

Clinical Subform	Therapy
Acute relapse	Pulsed high-dose glucocorticosteroids <i>Escalation:</i> Plasma exchange
Clinically isolated syndromes (CIS) with high risk of developing clinically definite MS	Interferon beta
Relapsing-remitting MS	First line: Interferon beta, glatiramer acetate Second line: IVIG, azathioprine With severe relapses and progression: Mitoxantrone
Secondary progressive MS	With relapses: Interferon beta Progressive: Mitoxantrone Second line: Cyclophosphamide
Primary progressive MS	No established therapy available
Relapsing progressive MS	No established therapy available

Neuroimmunotherapy; Editor in Chief, Karen L. Roos, M.D.; Guest Editor, Marinos C. Dalakas, M.D. *Seminars in Neurology*, Volume 23, Number 2, 2003. Address for correspondence and reprint requests: Bernd C. Kieseier, M.D., Department of Neurology, Heinrich-Heine-University, Moorenstrasse 5, 40225 Düsseldorf, Germany. <sup>1</sup>Department of Neurology, Heinrich-Heine-University, Düsseldorf, Germany. Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662. 0271-8235;p;2003,23,03,343,344,ftx,en;sin00265x.

